A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia

ALA PDT could be safely administered with a light dose up to 4 J/cm2 and demonstrated activity. Larger studies are needed to fully elucidate the MTD and efficacy of ALA-PDT.